Skip to content
AdvanCell logo — Changing the Course of Cancer Treatment

AdvanCell

Changing the Course of Cancer Treatment

Founded 2019 United States Boston, United States 106 employees Series B Biotechnology, Pharmaceutical

General Information

Company Name AdvanCell
Founded Year 2019
Location United States Boston, United States
Employees 106
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Offices as of Nov 2026
Boston, United States Richlands, Australia Sydney, Australia Newcastle, Australia Pullenvale, Australia SAN FRANCSICO, United States
Social

BounceWatch is an independent company data service, not affiliated with AdvanCell. To contact AdvanCell, visit advancell.com.au.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AdvanCell compare?

A PDF of AdvanCell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AdvanCell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Key Hire Nov 04, 2026

AdvanCell announced the appointment of Andy Porter as Chief People Officer.

Event Participation Oct 28, 2026

AdvanCell presented #ADVC001 Ph1 follow-up results at ESMO - European Society for Medical Oncology.

About AdvanCell

AdvanCell is a pioneering Australian company poised to make significant strides in the biotechnology and pharmaceutical sectors by revolutionizing cancer treatment. Founded in 2019, the company specializes in developing a cutting-edge pipeline of 212Pb-based Targeted Alpha Therapies.

The primary innovation of AdvanCell is its platform technology, which effectively addresses a major hurdle in Targeted Alpha Therapy: ensuring a reliable and scalable supply of the isotope 212Pb. This advancement positions the company favorably in the competitive landscape, capitalizing on its sophisticated drug discovery and preclinical processes.

Although AdvanCell is still in the clinical stage, its state-of-the-art facilities provide daily access to crucial isotopes, reinforcing its potential for growth and impactful results in cancer treatment.

With no disclosed last investment, this presents an appealing opportunity for investors looking to be at the forefront of transformative cancer therapies.

Business keywords: Radiopharmaceuticals, Targeted Alpha Therapy, 212Pb Isotope, Radioligand Discovery, Cancer Treatment, Drug Discovery, Preclinical Processes, Biopharmaceuticals, Isotope Supply Chain

No funding data available for AdvanCell yet.

AdvanCell Alternatives & Competitors

View All Alternatives
AdvanCell vs

Delivering the promise of radiopharmaceuticals to patients.

Private Equity
661 employees
Biopharma, Biotechnology
AdvanCell vs

Developing accessible oral small molecule therapies for the treatment of chronic diseases including...

IPO
219 employees
Biotechnology, Health Care
AdvanCell vs
Genprex, Inc.
Genprex, Inc. United States

Genprex is a gene therapy company focused on developing life-changing technologies for patients with...

Post-IPO Equity
24 employees
Biopharma, Biotechnology

FAQ About AdvanCell

Changing the Course of Cancer Treatment
AdvanCell was founded in 2019.
AdvanCell is headquartered in Boston, United States. As of Nov 2026, it also has offices in Richlands, Australia, Sydney, Australia, Newcastle, Australia, Pullenvale, Australia and SAN FRANCSICO, United States.
AdvanCell operates in Biotechnology and Pharmaceutical. Its work centres on Radiopharmaceuticals, Targeted Alpha Therapy, 212Pb Isotope and Radioligand Discovery.
AdvanCell has approximately 106 employees.
Top alternatives and competitors to AdvanCell include ITM Isotope Technologies Munich SE, Structure Therapeutics, Genprex, Inc., Advenchen Laboratories, LLC, Immunome, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AdvanCell and ITM Isotope Technologies Munich SE are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AdvanCell, https://www.bouncewatch.com/company/advancell, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout